Media Articles Related to Aplisol (Tuberculin)
Success short treatment against drug-resistant tuberculosis confirmed
Source: Respiratory / Asthma News From Medical News Today [2014.10.24]
The result of 10 years of collaboration between the Damien Foundation Belgium and the Institute of Tropical Medicine in Antwerp (ITM) could revolutionize global tuberculosis control.
A new way to attack multi-drug resistance in tuberculosis
Source: MRSA / Drug Resistance News From Medical News Today [2014.10.10]
Using a high-throughput screening assay, EPFL scientists have discovered two small molecules that could overcome the multidrug resistance of the bacterium that causes tuberculosis.
Source: MedicineNet Neutropenia Specialty [2014.01.24]
Title: Tuberculosis (TB)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/24/2014 2:28:22 AM
Short TB Regimens Fall Flat (CME/CE)
Source: MedPage Today Infectious Disease [2014.10.23]
(MedPage Today) -- On the plus side, WHO says tuberculosis incidence is improving.
WHO report: TB is more widespread than previously estimated
Source: HIV / AIDS News From Medical News Today [2014.10.22]
Due to improvements in information gathering, a higher incidence of tuberculosis has been exposed in a new World Health Organization report.
Published Studies Related to Aplisol (Tuberculin)
The comparative performance of the single intradermal comparative tuberculin test in Irish cattle, using tuberculin PPD combinations from different manufacturers. [2011.07.05]
Ireland currently obtains its avian and bovine tuberculin purified protein derivatives (PPDs) from a single source... In this study, the precision of the guinea pig bio-assay to assess tuberculin potency was low and therefore Ireland should maintain its practice of periodically assessing potency in naturally infected cattle, even though this is not currently required under WHO, OIE or EU Regulations.
Tuberculin skin-test reactions are unaffected by the severity of hyperendemic intestinal helminth infections and co-infections. [2010.08]
The tuberculin skin test (TST) quantifies cell-mediated immunity to tuberculosis antigens. Helminths suppress cell-mediated immunity, so we studied the effect of helminth infection and deworming on the TST in a randomized, double-blind, placebo-controlled study in an indigenous Amazon community (N = 195)...
Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. [2010.05.01]
Understanding the epidemiology and clinical course of tuberculosis is hampered by the absence of a perfect test for latent tuberculosis infection. The tuberculin skin test (TST) is widely used but suffers poor specificity in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in individuals with human immunodeficiency virus (HIV) infections...
The effect of tuberculin testing on the development of cell-mediated immune responses during Mycobacterium bovis infection. [2006.11.15]
Protection against tuberculosis (TB) is associated with Th1-type cell-mediated immunity (CMI).
The effect of Johne's vaccination on tuberculin testing in farmed red deer (Cervus elaphus). [2005.08]
AIM: To assess the degree of interference with bovine tuberculin testing in farmed red deer that vaccination of young deer with an oil-adjuvanted vs aqueous formulation of live attenuated Mycobacterium paratuberculosis Strain 316F vaccines would be likely to cause, and to compare immunological responses between vaccine formulations... CONCLUSIONS: Vaccination of farmed deer with an oil-adjuvanted Johne's vaccine has the potential to cause significant interference with routine tuberculin skin testing. The cross-reactivity should decline with time and the CCT should be able to clear MCT-positives, but there is a risk of false-positives to the blood test for tuberculosis (BTB), due to high persistent levels of antibody. The CCT could be used as a primary skin test in vaccinated deer on some farms. The Aqueous Ptb caused fewer problems with skin testing and produced significantly less bovine antibody than the Oil-adjuvant Ptb, but stimulated persistent cell-mediated immune responses that may provide some protection against Johne's disease.
Clinical Trials Related to Aplisol (Tuberculin)
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) [Recruiting]
Dose comparison study of tuberculin purified protein derivative (PPD)Aplisol with the
standard tuberculin purified derivative (PPD-S2).
A Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON�-TB, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI [Recruiting]
Tuberculosis (TB) continues to be the most important bacterial infection worldwide and
therefore new improved diagnostic tests are needed to help doctors in diagnosing TB.
We are investigating a new skin test named C-Tb. Like the current tuberculin skin test
(PPD), the C-Tb test is injected just under the skin and will, when positive, show redness
and/or swelling at the injection site while a negative test will leave no reactions.
The aim of this trial is to test the C-Tb skin test in volunteers. The volunteers are
divided into four groups:
- Negative control group: Must have no history of exposure to a person with tuberculosis
- Occasional contact: Must be in contact with a person with tuberculosis disease between
6 hours/week and 6 hours/day
- Close contact: Must be in close contact with a person with tuberculosis disease for
more than 6 hours/day for at least five days
- Positive control group: Must have a confirmed tuberculosis disease within the last 3
The goals of this clinical trial are:
- To compare the C-Tb test to a blood test, the QuantiFERON test.
- To compare the C-Tb test to the PPD test that is currently being used.
- To assess the safety of the C-Tb test.
Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses [Not yet recruiting]
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum
Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a
positive test result will show as redness and/or induration at the injection site, while a
negative test will leave no reactions.
The aim of this study is to address if the size of induration and the sensitivity of C-Tb is
influenced by concomitant injections of C-Tb and Tuberculin. Furthermore, the intention is
to evaluate the safety of C-Tb when injected alone or concomitantly with Tuberculin.
Optimization of Tuberculosis Intradermal Skin Test [Recruiting]
The only test available for in vivo diagnosis of tuberculosis is the intradermal injection
of tuberculin according to the Mantoux method (also named tuberculosis skin test or PPD skin
The tuberculin skin test is based on a delayed-type hypersensitivity skin reaction However,
this test needs to be performed by trained personnel, presents problem of reproducibility,
and its interpretation is not well standardized (measure in millimeters of skin induration
48 to 72 hours after the PPD skin test).
The new generation BD micro needle used in this study should solve the technical
difficulties; intradermal administration of tuberculin could then be made by any personnel.
A non-invasive and objective instrumental method of reading the test will be also tested .
Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection [Active, not recruiting]
To quantitate in an HIV-infected population the percentage of patients demonstrating the
"booster" phenomenon (attainment of a positive response to a second tuberculin purified
protein derivative skin test when the first skin test was negative); to determine the
relationship between the booster phenomenon and CD4-positive lymphocyte cell counts; to
detect any relationship between the booster phenomenon and HIV exposure category.
The accuracy of skin testing to detect Mycobacterium tuberculosis (MTb) infection is
dependent upon the host's ability to mount a delayed-type hypersensitivity (DTH) reaction;
however, the DTH response may be impaired or absent in patients with impaired cell-mediated
immunity, a classic characteristic of HIV infection. Patients in whom immunity is diminished,
but not absent, may test negative the first time a purified protein derivative skin test for
MTb is administered, but if the same skin test is repeated, a positive DTH response may then
be elicited. This occurrence is known as the "booster" phenomenon.
Reports of Suspected Aplisol (Tuberculin) Side Effects
Injection Site Erythema (3),
Erythema Multiforme (3),
Gait Disturbance (3),
Application Site Reaction (2),
Chest Pain (2),
Injection Site Reaction (2),
Rash Papular (2),
Injection Site Pruritus (2),
Injection Site Urticaria (1), more >>